Aleva Neurotherapeutics raises CHF4.0m in Series B funding
Aleva Neurotherapeutics, a company developing next-generation implants for Deep Brain Stimulation (DBS) in major neurological indications such as Parkinson´s disease or depression, has closed a Series B financing round totalling CHF 4.0 million. Banexi Ventures Partners acted as a lead investor in the financing, with selected private investors also participating
